![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, January 04, 2016 2:43:36 PM
It appears that management deliberately mislead shareholders when the CEO firmly stated there was 'no reason' why the FDA won't approve by the end of the year. At the same time, management increased the share count by a massive 35%.
There is no FDA coming. If the FDA were coming, there would be no need to increase the share count. Remember, shareholders were told of a massive $50 million deal that is waiting for FDA approval. With $50 million waiting patiently on the sidelines, there would be no need to increase the share count once the FDA approves.
BIEL's increase in the share count is a clear sign of FDA rejection. However, management will no admit this as they have 4 billion shares to dump.
FEATURED Cannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing • Jul 11, 2024 8:21 AM
ECGI Holdings Enhances Board with Artificial Intelligence (AI) Expert Ahead of Allon Apparel Launch • ECGI • Jul 10, 2024 8:30 AM
Avant Technologies to Meet Unmet Needs in AI Industry While Addressing Sustainability Concerns • AVAI • Jul 10, 2024 8:00 AM
Panther Minerals Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • PURR • Jul 9, 2024 9:00 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM